27Apr
[Video] Six Things You Need to Know About Life Sciences M&A During and After COVID-19
While life sciences M&A activity soared to a new high in 2019, the uncertainty surrounding the pandemic has led to a slow down in deal making activity. However, as the crisis in the U.S. subsides and the U.S. economy stabilizes, we expect life...
By:
Arnall Golden Gregory LLP
Related
On October 10, 2019, the National Labor Relations Board (“Board”) took a welcomed step in clarifyi...
Read More >
Germany’s cabinet has approved draft legislation designed to tighten the country’s foreign investm...
Read More >
HIPAA compliance for self-insured plans is not black and white. The nature and extent of a self-insu...
Read More >
The rapid and significant decline in stock trading prices of many public companies due to the effect...
Read More >
The U.S. District Court for the District of Columbia upheld a rule that expanded the maximum length ...
Read More >
Resolution 2103 of January 27, 2021, of the Superintendence of Industry and Commerce (“SIC”) sets ...
Read More >